J
Julia K. Pagan
Researcher at New York University
Publications - 21
Citations - 2155
Julia K. Pagan is an academic researcher from New York University. The author has contributed to research in topics: Ubiquitin ligase & Ubiquitin. The author has an hindex of 15, co-authored 19 publications receiving 1883 citations. Previous affiliations of Julia K. Pagan include QIMR Berghofer Medical Research Institute & University of Queensland.
Papers
More filters
Journal ArticleDOI
Mechanisms and function of substrate recruitment by F-box proteins
TL;DR: The evolution of substrate recruitment by F-box proteins, the dysregulation of substrates in disease and potential avenues for F- box protein-directed disease therapies are focused on.
Journal ArticleDOI
SCF ubiquitin ligase targeted therapies
TL;DR: This Review explores and discusses potential strategies to target SCF-mediated biological processes to treat human diseases and describes SCF ubiquitin ligases as promising drug targets.
Journal ArticleDOI
FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas
Shanshan Duan,Lukas Cermak,Julia K. Pagan,Mario Rossi,Cinzia Martinengo,Paola Francia di Celle,Bjoern Chapuy,Margaret A. Shipp,Roberto Chiarle,Michele Pagano +9 more
TL;DR: It is shown that BCL6 is targeted for ubiquitylation and proteasomal degradation by a SKP1–CUL1–F-box protein (SCF) ubiquitin ligase complex that contains the orphan F-boxprotein FBXO11, and proposed that mutations and deletions in FBxO11 contribute to lymphomagenesis through BCL 6 stabilization.
Journal ArticleDOI
PTEN counteracts FBXL2 to promote IP3R3- and Ca2+-mediated apoptosis limiting tumour growth
Shafi Kuchay,Carlotta Giorgi,Carlotta Giorgi,Daniele Simoneschi,Julia K. Pagan,Sonia Missiroli,Anita Saraf,Laurence Florens,Michael P. Washburn,Michael P. Washburn,Ana Collazo-Lorduy,Mireia Castillo-Martin,Carlos Cordon-Cardo,Said M. Sebti,Paolo Pinton,Michele Pagano +15 more
TL;DR: It is identified that the F-box protein FBXL2 binds IP3R3 and targets it for ubiquitin-, p97- and proteasome-mediated degradation to limit Ca2+ influx into mitochondria and provide proof-of-principle that inhibiting IP3 R3 degradation in PTEN-deregulated cancers represents a valid therapeutic strategy.
Journal ArticleDOI
SnapShot: F Box Proteins II.
TL;DR: Jetlag Tim txn activator, circadian rhythms Ppa Prd homeobox txn factor, development CG4643/dFsn Wnd kinase, synaptic growth Morgue Th/DIAP1 Ub ligase, inhibitor of apoptosis Pall unknown phagocytosis of apoptotic cellsRca1 unknown APC/C inhibitor.